SIMVASTATIN as a potential protective strategy against doxorubicin-induced cardiotoxicity - Top-Institutions - MDSpire

SIMVASTATIN as a potential protective strategy against doxorubicin-induced cardiotoxicity

  • By

  • Barbara Pala

  • Mariagrazia Piscione

  • Maria Carmela Di Marcantonio

  • Francesco Cribari

  • Roberta Vitale

  • Thomas Baldi

  • Ada Popolo

  • Gabriella Mincione

  • June 9, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Cardiology

  • #2

    Spanish National Centre for Cardiovascular Research
    Spanish National Centre for Cardiovascular Research

    Madrid, Spain

    Key Differentiators

    • Cardiology

  • #3

    German Society for Pediatric Cardiology and Congenital Heart Defects
    German Society for Pediatric Cardiology and Congenital Heart Defects

    Berlin, Germany

    Key Differentiators

    • Pediatric Cardiology

Original Source(s)

SIMVASTATIN as a potential protective strategy against doxorubicin-induced cardiotoxicity

  • by Barbara Pala, Mariagrazia Piscione, Maria Carmela Di Marcantonio, Francesco Cribari, Roberta Vitale, Thomas Baldi, Ada Popolo, Gabriella Mincione

  • June 9, 2026

Related Content

Body mass index, regional adipose deposition, and clinical outcomes in non-ischaemic dilated cardiomyopathy: a prospective cohort study

Heart failure prediction in dysglycaemia: are we ready to trust the proteome?

Effects of exercise training on nitric oxide metabolites in heart failure with reduced or preserved ejection fraction: a secondary analysis of the SMARTEX-HF and OptimEx-Clin trials